2018 American Transplant Congress
The Clinical Significance of Pretransplant C1q Assay Status in Positive Crossmatch Kidney Transplantation
Background: Patients with a pretransplant donor-specific antibodies (DSA) are at higher risk for antibody-mediated rejection (AMR). However, not all DSA have the same pathogenetic potential.…2018 American Transplant Congress
Searching for Recipient-HLA Class II and Donor-HLA-Derived Peptide Complexes Inducing Protective Effect against De Novo Donor-Specific HLA Antibodies Formation in Kidney Transplantation
De novo donor-specific HLA antibodies (dnDSA) are recognized as a risk factor for late deterioration of renal allograft function. dnDSA production occurs via the indirect…2018 American Transplant Congress
Dual Inhibition of PI3K and mTORC2 Causes ERK Hyperactivation Induced by HLA-II Antibody in Human Endothelium
Pathology and Laboratory Medicine, David Geffen School of Medicine, UCLA, Los Angeles, CA.
Background: Endothelial cells (EC) line the inner surface of blood vessels and serve as the interface between recipient circulating blood and the donor allograft. Transplant…2018 American Transplant Congress
The Complexity of HLA-DQ
Northwestern University, Chicago.
Historically, HLA-DQ antigens and antibodies (Ab) were difficult to classify due to the lack of serological typing reagents. However, with the advent of molecular typing…2018 American Transplant Congress
The Results of Plasmapheresis and Anti-CD20 Based Desensitization without Intravenous Immunoglobulin in Positive Crossmatch Kidney Transplants
Asan Medical Center, Seoul, Korea.
This study examined the mid-term clinical outcomes in positive crossmatch kidney transplants (XMKT) for patients who received desensitization with plasmapheresis (PP) and anti-CD20 based regimens…2017 American Transplant Congress
Kidney Transplant Rejection Associated with DQ Eplet Mismatches.
The presence of anti-HLA antibodies is associated with acute rejection, allograft dysfunction and earlier graft loss. HLA antibodies are recognized as being specific to these…2017 American Transplant Congress
Safety and Activity of Anti-C1s Humanized Monoclonal Antibody TNT009 in Late Antibody-Mediated Kidney Allograft Rejection – Results of a First-in-Human Phase 1 Trial.
Study purpose:The classical pathway (CP) of complement may significantly contribute to antibody-mediated rejection (ABMR). Blockade of CP key component C1 may be a promising strategy…2017 American Transplant Congress
Update of a Placebo-Controlled Trial of C1 Esterase Inhibitor for Prevention of Antibody Mediated Rejection (ABMR) in Highly-HLA Sensitized Patients.
Kidney Transplant, Cedars-Sinai Medical Center, LA, CA
INTRODUCTION: Desensitization (DES) strategies focus primarily on antibody reduction using IVIG, rituximab ± PLEX to prevent DSA-induced ABMR and rebound B-cell activity. Pathologic features of…2017 American Transplant Congress
Healthcare Resource Utilization for Patients with Donor-Specific Antibodies Post-Kidney Transplantation.
Formation of de novo donor-specific antibodies (dnDSA) against human leukocyte antigens (HLA) contributes to inferior kidney transplant (KT) outcomes. No data exist on healthcare resource…2017 American Transplant Congress
Isolated Angiotensin II Receptor Type I Antibodies (AT1R) Are Not Associated with Active Antibody Mediated Rejection (ABMR) in Pediatric Renal Transplant Recipients.
Comprehensive Transplant Center, Cedars Sinai Medical Center, Los Angeles, CA
Intro: Donor specific antibodies (DSAs) detected post transplant are associated with ABMR and graft dysfunction. The role of non-HLA antibodies especially angiotensin II receptor type…
- « Previous Page
- 1
- …
- 24
- 25
- 26
- 27
- 28
- …
- 47
- Next Page »